The U.S. Food and Drug Administration has approved daraxonrasib, a new oral medication that has demonstrated the potential to significantly extend survival for pancreatic cancer patients. The drug, manufactured by Revolution Medicines and to be sold under the brand name Rasonque, targets a mutated protein called KRAS, which fuels cancer cell growth.
Clinical trial results indicated that patients treated with daraxonrasib had a median overall survival of 13.2 months, a substantial increase compared to the 6.7 months observed in the chemotherapy group. This near doubling of survival time has been described by oncologists as “life-altering” and “remarkable.”
KRAS mutations have long been a target for cancer researchers, often described as a “stuck accelerator” in cancer cells. While recent drugs have targeted specific versions of KRAS, daraxonrasib appears to be effective against multiple variations, suggesting a broader potential application across various cancer types, including colorectal and lung cancer.
Former U.S. Sen. Ben Sasse, R-Neb., publicly shared his experience with daraxonrasib earlier this year. Sasse, who is battling Stage 4 pancreatic cancer, described experiencing severe skin toxicity, which he characterized as leaving his skin bloody and “bubbling.” He noted that his skin and face felt “nuclear” due to the treatment, though he also stated the drug was giving him more time with his family.
Physicians acknowledge the potential for skin toxicity as a side effect. However, Dr. Nicholas Hornstein, a medical oncologist, noted that this toxicity is generally less severe than what Sasse reported. He also emphasized that early involvement of onco-dermatology and the use of specific agents can significantly mitigate these side effects.
Acting FDA Commissioner Kyle Diamantas stated that the approval of Rasonque provides a critical new option for patients facing pancreatic cancer, a historically difficult-to-treat disease. The FDA highlighted the swift review process undertaken by its scientists to bring this significant advancement to patients.